Friday 18 October 2019 - 18:25
In Business 39 Years - Since 1980
New Price Reductions for Fifteen Products: As Much as 33% -- October 10, 2019.
FREE SHIPPING TO THE U.S. AND 33 OTHER COUNTRIES! [Read more].
Search:
P-7600 PKC412, >99%
Synonyms : [CGP41251] [4'-N-Benzoyl Staurosporine] [Midostaurin]
Related Terms : [Rydapt]
- Size
- US $
- €
- £
- ¥
- 1 mg
- 41
- 36
- 31
- 4,400
- Add to Cart
- Out of stock
- 5 mg
- 99
- 88
- 76
- 10,700
- Add to Cart
- Out of stock
- 10 mg
- 166
- 148
- 128
- 18,000
- Add to Cart
- Out of stock
- 25 mg
- 331
- 296
- 256
- 35,900
- Add to Cart
- Out of stock
- 50 mg
- 459
- 411
- 355
- 49,800
- Add to Cart
- Out of stock
- 100 mg
- 775
- 695
- 600
- 84,100
- Add to Cart
- Out of stock
- 200 mg
- 1,290
- 1,157
- 999
- 139,900
- Add to Cart
- Out of stock
- 500 mg
- 1,870
- 1,677
- 1,449
- 202,800
- Add to Cart
- Out of stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 33 Other Countries
- M.W. 570.64
- C35H30N4O4
- [120685-11-2]
- M.I. 14: 6185
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 5 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.
- The staurosporine analog, PKC412, inhibits a variety of serine/threonine and tyrosine kinases including PKC (IC50 = 50 nM), cyclic AMP-dependent protein kinase (IC50 = 2.4 µM), S6 kinase (IC50 = 5.0 µM), and EGFR (epidermal growth factor receptor) tyrosine-kinase activity (IC50 = 3.0 µM). Meyer, T., et al. "A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity." Int. J. Cancer 43: 851-856 (1989).
- PKC412 inhibits autophosphorylation of platelet-derived growth factor (PDGF) receptor in BALB/c 3T3 cells at submicromolar concentrations. Andrejauskas-Buchdunger, E. and Regenass, U. "Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251." Cancer Research, 52: 5353-5358 (1992).
- PKC412 strongly blocks the proliferation of ras-transformed pancreatic cancer cells (TUC-3) by causing apoptosis and induction of phenotypic reversion. Way, D., et al. "A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti-ras peptide." Cancer Chemother. Pharmacol. 49: 429-437 (2002).
- PKC412 suppresses Akt activity by blocking serine phosphorylation in the kinase activation loop and induces apoptosis in myeloma cell lines. Bahlis, N.J., et al. "N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells." Leuk. Lymphoma 46: 899-908 (2005).
- PKC412 selectively inhibits T lymphocyte production of TNF-α (tumor necrosis factor - alpha) with an IC50 of 0.5 µM. Si, M.S., et al. "Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production." Int. Immunopharmacol. 5: 1141-11419 (2005).
- Not available in some countries; not available to some institutions; may not be sold for some uses.
- Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
